曲妥珠单抗德鲁替康用于对基于曲妥珠单抗的化疗耐药的复发性子宫浆液性癌
Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy.
作者信息
McNamara Blair, Bellone Stefania, Demirkiran Cem, Hartwich Tobias Max Philipp, Santin Alessandro D
机构信息
Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA.
出版信息
Gynecol Oncol Rep. 2023 Jun 4;48:101219. doi: 10.1016/j.gore.2023.101219. eCollection 2023 Aug.
BACKGROUND
Treatment of uterine serous carcinoma (USC) is challenging; effective treatment options for metastatic and recurrent disease are needed.
CASE
A 68-year-old woman with recurrent, metastatic, USC overexpressing HER2/neu experienced durable response to the antibody drug conjugate (ADC) trastuzumab-deruxtecan (T-DXd), after failing multiple standard and experimental treatments targeting HER2/neu. She experienced a significant reduction in disease burden, disappearance of metastatic back bone pain as well as normalization of CA-125 quickly after starting treatment. Her disease continued to show response to treatment over 5 months and 7 cycles of T-DXd therapy. She did not experience any dose-limiting side effects and tolerated treatment with 5.4 mg/kg T-DXd without issue.
CONCLUSION
T-DXd may present a new treatment option for chemotherapy-resistant uterine serous carcinoma.
背景
子宫浆液性癌（USC）的治疗具有挑战性；需要针对转移性和复发性疾病的有效治疗方案。
病例
一名68岁复发性、转移性USC且HER2/neu过表达的女性，在针对HER2/neu的多种标准和实验性治疗失败后，对抗体药物偶联物（ADC）曲妥珠单抗-德曲妥珠单抗（T-DXd）产生了持久反应。开始治疗后，她的疾病负担显著减轻，转移性背痛消失，CA-125也迅速恢复正常。在接受5个多月的治疗和7个周期的T-DXd治疗后，她的疾病仍持续显示出对治疗的反应。她没有出现任何剂量限制性副作用，能够耐受5.4mg/kg的T-DXd治疗。
结论
T-DXd可能为化疗耐药的子宫浆液性癌提供一种新的治疗选择。
Zotero 插件